Company news

Dare Bioscience, Inc. news in 2020

Dare Bioscience, Inc.'s news releases, calls and decks from 2020, newest first.

View company

Daré Bioscience Announces Positive Topline Results From DARE-BVFREE, a Phase 3 Trial of DARE-BV1 in Patients Diagnosed with Bacterial Vaginosis

December 6, 2020

Daré Bioscience Reports Third Quarter 2020 Financial Results and Provides Company Update

November 11, 2020

Daré Bioscience to Host Third Quarter 2020 Financial Results and Company Update Conference Call and Webcast on November 12, 2020

November 4, 2020

Daré Bioscience Receives $0.9 million Under the Current Grant Supplement Award for Continued Development of its User-Controlled, Long Acting Reversible Contraceptive (DARE-LARC1)

September 20, 2020

Daré Bioscience Announces Participation in Two Upcoming Virtual Conferences

September 7, 2020

Daré Bioscience and Avomeen Form Strategic Partnership to Accelerate the Development of Daré’s Novel Pipeline of Women’s Health Programs

August 31, 2020

Daré Bioscience Announces Publication of DARE-BV1 Proof of Concept Study for the Treatment of Bacterial Vaginosis

August 19, 2020

Daré Bioscience Reports Second Quarter 2020 Financial Results and Provides Company Update

August 11, 2020

Daré Bioscience to Host Second Quarter 2020 Financial Results and Company Update Conference Call and Webcast on August 12, 2020

August 4, 2020

Daré Bioscience Announces Initiation of Phase 1 Clinical Trial of DARE-HRT1, a Novel Intravaginal Ring Designed to Deliver Non-oral, Bio-identical Hormone Therapy for the Treatment of Menopausal Symptoms

July 26, 2020

Daré Bioscience Regains Compliance with Nasdaq Minimum Equity Rule and Secures Capital to Advance Product Candidates

February 5, 2020

Daré Bioscience Schedules Conference Call for January 22, 2020 to Discuss Ovaprene® Licensing Agreement and General Corporate Update

January 14, 2020

Calls in 2020

Decks in 2020